Beatriz M. Carreno
Research Associate Professor of Pathology and Laboratory Medicine
Member, University of Pennsylvania, Parker Institute for Cancer Immunotherapy
Member, University of Pennsylvania, Institute for Immunology
Member, University of Pennsylvania, Center for Cellular Immunotherapies
Department: Pathology and Laboratory Medicine
Graduate Group Affiliations
Contact information
PCAM South Tower, 8th Floor
3400 Civic Blvd
Philadelphia, PA 19104
3400 Civic Blvd
Philadelphia, PA 19104
Office: 215-573-7044
Lab: 215-573-4931
Lab: 215-573-4931
Email:
bcarreno@upenn.edu
bcarreno@upenn.edu
Publications
Links
Search PubMed for articles
University of Pennsylvania, Center for Cellular Immunotherapies site
Search PubMed for articles
University of Pennsylvania, Center for Cellular Immunotherapies site
Education:
BS
Universidad Simon Bolivar, Caracas, Venezuela, 1981.
PhD (Microbiology)
Georgetown University School of Medicine, 1989.
BS
Universidad Simon Bolivar, Caracas, Venezuela, 1981.
PhD (Microbiology)
Georgetown University School of Medicine, 1989.
Post-Graduate Training
Visiting Postdoctoral Fellow, Neuro-immunology, NINDS, NIH , 1989-1991.
Postdoctoral Research Associate, Genetics, Washington University School of Medicine, 1991-1995.
Permanent linkVisiting Postdoctoral Fellow, Neuro-immunology, NINDS, NIH , 1989-1991.
Postdoctoral Research Associate, Genetics, Washington University School of Medicine, 1991-1995.
Description of Itmat Expertise
My research interests have centered on questions related to the generation and modulation of anti-tumor human T cell immunity and how these responses can be harnessed to develop better immune therapeutics. My laboratory develops methods for (1) identification of tumor antigens, (2) improvement of dendritic cell (DC)-based vaccines and (3) expansion of tumor-specific T cells for clinical applications. Our lab has well-documented experience in the identification and expansion of tumor (shared and neoantigen)-specific CD8+ T cells derived from cancer patients and the development of cellular immunotherapies.Selected Publications
Linette GP, Bear AS, Carreno BM: Facts and hopes in immunotherapy strategies targeting antigens derived from KRAS mutations. Clin Cancer Res Jan 2024 Notes: doi: 10.1158/1078-0432.CCR-23-1212. Online ahead of print.Lee IK, Sharma N, Noguera-Ortega E, Liousia M, Baroja ML, Etersque JM, Pham J, Sarkar S, Carreno BM, Linette GP, Puré E, Albelda SM, Sellmyer MA.: A genetically encoded protein tag for control and quantitative imaging of CAR T cell therapy. Mol Ther 31(12): 3564-3578, Dec 2023.
Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang WT, Vogl DT, Waxman AJ, Lacey SF, Gonzalez VE, Fraietta JA, Gupta M, Kulikovskaya I, Tian L, Chen F, Koterba N, Bartoszek RL, Patchin M, Xu R, Plesa G, Siegel DL, Brennan A, Nelson AM, Ferthio R, Cosey A, Shea KM, Leskowitz R, Four M, Wilson WV, Miao F, Lancaster E, Carreno BM, Linette GP, Hexner EO, Young RM, Bu D, Mansfield KG, Brogdon JL, June CH, Milone MC, Stadtmauer EA.: Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy. Blood Cancer Discov 4(2): 118-133, Mar 2023.
Bear, A.S., Nadler, R.B., Scholler, J., Vonderheide, R.H., Linette, G.P., Carreno, B.M.: TCR1020 specific for KRAS G12V restricted to HLA-A*11:01 exhibits potent and precise antigen specificity for clinical development. AACR- Targeting Ras, Philadelphia, PA Mar 2023 Notes: Oral Presentation.
Smole, A., Benton, A., Poussin, M.A., Eiva, M.A., Mezzanotte, C., Camisa, B., Greco, B., Sharma, P., Minutolo, N.G., Gray, F., Bear, A.S., Baroja, M.L., Cummins, C., Xu, C., Sanvito, F., Goldgewicht, A.L., Blanchard, T., Rodriguez-Garcia, A., Klichinsky, M., Bonini, C., June, C.H., Posey, A.D., Linette, G.P., Carreno, B.M., Casucci, M., Powell, D.J.: Expression of inducible factors reprograms CAR-T cells for enhanced function and safety. Cancer Cell 40(12): 1470-1487, Dec 2022.
Olson, T.S., Frost, B.F., Duke, J.L., Dribus, M., Xie, H.M., Prudowsky, Z.D., Furutani, E., Gudera, J., Shah, Y.B., Ferriola, D., Dinou, A., Pagkrati, I., Kim, S., Xu, Y., He, M., Zheng, S., Nijim, S., Lin, P., Xu, C., Nakano, T., Oved, J.H., Carreno, B.M., Bolon, Y., Gadalla, S.M., Marsh, S.G., Paczesny, S., Lee, S.J., Monos, D.S., Shimamura, A., Bertuch, A.A., Gragert, L., Spellman, S., Babushok, D.V.: Pathogenicity and impact of HLA class I alleles in aplastic anemia patients of different ethnicities. JCI Insight 7(22): e163040, Nov 2022.
Apodaca, K., Xu, C., Stanton, K., Carreno, B.M., Linette, G.P.: Determining the Histocompatibility Barriers between Universal CAR T (UCART) cells and NK cells. SITC Annual Meeting 2022, Boston, MA Nov 2022 Notes: Poster Presentation.
Nadler, R.B., Bear, A.S., Saporito, R.J., Scholler, J., Vonderheide, R.H., Linette, G.P., Carreno, B.M. : TCRs directed to mutant KRAS display distinct antigen recognition motifs and minimal cross-reactivity to non-cognate antigens. AACR-Pancreas Cancer Collective Meeting, Boston MA Sept 2022 Notes: Poster Presentation.
Bear, A.S., Nadler, R.B., Scholler, J., Vonderheide, R.H., Linette, G.P., Carreno, B.M.: Mutant KRAS-specific T cell receptors directed against prevalent G12D and G12V variants exhibit potent cytotoxic activity and CD8 co-receptor independence. AACR- Pancreas Cancer Collective Meeting, Boston MA Sept 2022 Notes: Oral Presentation.
Richters, M.M., Cotto, K.C., Kiwala, S., Xia, H., Carreno, B.M., Dunn, G.P., Ribas, A., Griffith, O.L., Griffith, M.: pVACsplice: Predicting neoantigens from tumor-specific alternative splicing events derived from cis-acting regulatory mutations using whole exome and RNA sequencing data. AACR Annual Meeting 2022, New Orleans, LA April 2022 Notes: Poster Presentation.